News
PTGX
31.71
+1.44%
0.45
Weekly Report: what happened at PTGX last week (0513-0517)?
Weekly Report · 1d ago
Protagonist Therapeutics Presents Long-Term Follow-up Of Rusfertide Phase 2 REVIVE Study Open Label Extension At The EHA 2024 Congress
Additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Association Congress being held in Madrid, 2024. There will also be a published abstract showing the absence of QTc prolongation.
Benzinga · 05/14 20:28
Weekly Report: what happened at PTGX last week (0506-0510)?
Weekly Report · 05/13 11:24
Protagonist Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
Dow Jones · 05/09 19:11
HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $38 Price Target
Benzinga · 05/09 19:00
Buy Rating Affirmed for Protagonist Therapeutics on Strong Financials and Promising Clinical Trials
TipRanks · 05/09 10:44
Protagonist Therapeutics Is Maintained at Market Outperform by JMP Securities
Dow Jones · 05/08 18:19
Protagonist Therapeutics Price Target Raised to $45.00/Share From $42.00 by JMP Securities
Dow Jones · 05/08 18:19
JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $45
Benzinga · 05/08 18:09
Protagonist Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Protagonist Therapeutics Inc reported quarterly adjusted earnings of $3.26 per share for the quarter ended in March. The company reported quarterly income of $207.34 million. Wall Street expected the company to report earnings of -67 cents for the same quarter last year. The average analyst rating on the company's shares is "buy"
Reuters · 05/08 07:39
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Nevro Corp (NVRO) and Precigen (PGEN)
TipRanks · 05/08 05:10
Protagonist Therapeutics: Strong Buy Rating on Robust Financials and Promising Pipeline
TipRanks · 05/08 01:55
Protagonist Therapeutics, Inc. Form 10-Q: Condensed Consolidated Financial Statements (unaudited)
Press release · 05/07 21:52
Protagonist GAAP EPS of $3.26, revenue of $254.95M
Seeking Alpha · 05/07 21:47
Protagonist Ther: Quarterly report
Press release · 05/07 21:37
Protagonist Therapeutics: Q1 Earnings Snapshot
Protagonist Therapeutics Inc. Reports first-quarter net income of $207.3 million. The biopharmaceutical company posted revenue of $255 million in the period. The company's results surpassed Wall Street expectations for the quarter. The company says it had net income of $3.26 per share.
Barchart · 05/07 15:22
Weekly Report: what happened at PTGX last week (0429-0503)?
Weekly Report · 05/06 11:31
Protagonist Therapeutics Inc <PTGX.OQ> expected to post earnings of $1.19 a share - Earnings Preview
Protagonist Therapeutics Inc expected to post earnings of $1.19 a share - Earnings Preview. The company is expected to report revenue of $120 million for the period ending March 31 2024. The average analyst estimate for the company's quarterly revenue is $120m.
Reuters · 04/30 12:15
Weekly Report: what happened at PTGX last week (0422-0426)?
Weekly Report · 04/29 11:39
Weekly Report: what happened at PTGX last week (0415-0419)?
Weekly Report · 04/22 11:27
More
Webull provides a variety of real-time PTGX stock news. You can receive the latest news about Protagonist Ther through multiple platforms. This information may help you make smarter investment decisions.
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).